Cadrenal Therapeutics, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 822 A1A NORTH, PONTE VEDRA, FL, 32082
Mailing Address 822 A1A NORTH, PONTE VEDRA, FL, 32082
Phone 904-300-0701
Fiscal Year End 1231
EIN 880860746
Financial Overview
FY2024
$10.12M
Total Assets
$2.68M
Total Liabilities
$10.00M
Cash & Equivalents
$-8.73
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | December 31, 2025 | View on SEC |
| S-1 IPO registration statement | December 29, 2025 | View on SEC |
| 8-K Current report of material events | December 23, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 23, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 16, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 16, 2025 | View on SEC |
| 8-K Current report of material events | December 16, 2025 | View on SEC |
| 8-K Current report of material events | December 11, 2025 | View on SEC |
| 4 Insider stock transaction report | December 3, 2025 | View on SEC |
| 3 Initial insider ownership report | December 3, 2025 | View on SEC |
Material Events
8-K Acquisition December 11, 2025
High Impact
- Cadrenal Therapeutics acquired VLX-1005 and its related compounds from Veralox Therapeutics Inc., expanding its drug pipeline.
- The acquisition significantly diversifies Cadrenal's portfolio beyond CAD-1883, reducing risk and opening new potential revenue streams.
Insider Trading
SELL 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.